BG104484A - Сайт - специфично получаване на конюгати от полиетилен- гликол - grf - Google Patents

Сайт - специфично получаване на конюгати от полиетилен- гликол - grf

Info

Publication number
BG104484A
BG104484A BG104484A BG10448400A BG104484A BG 104484 A BG104484 A BG 104484A BG 104484 A BG104484 A BG 104484A BG 10448400 A BG10448400 A BG 10448400A BG 104484 A BG104484 A BG 104484A
Authority
BG
Bulgaria
Prior art keywords
site
peg
specific preparation
congrates
grf
Prior art date
Application number
BG104484A
Other languages
English (en)
Other versions
BG64815B1 (bg
Inventor
Francesco Veronese
Paolo Caliceti
Oddone Schiavon
Original Assignee
Applied Research Systems ARS Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding N.V. filed Critical Applied Research Systems ARS Holding N.V.
Publication of BG104484A publication Critical patent/BG104484A/bg
Publication of BG64815B1 publication Critical patent/BG64815B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Изобретението се отнася до метод за сайт-специфичен препарат на hGRF-PEG конюгати, съдържащи един или повече РЕG единици (за mol hGR), ковалентно свързани с Лизин12 и/или Лизин21, и/или N алфа, при който метод реакцията на конюгация между hGRF пептида и активиран РЕG се провежда в разтвор и желаният hGRF-PEG конюгат може да бъде пречистен чрез хроматография. Изобретението се отнася също до конюгатите, приготвени по този метод, до тяхното използване при третиране, превантивност и диагностика на недостатъчност на растежен хормон.
BG10448A 1997-12-03 2000-05-29 Сайт - специфично получаване на конюгати от полиетилен- гликол - grf BG64815B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121264A EP0922446A1 (en) 1997-12-03 1997-12-03 Solution-phase site-specific preparation of GRF-PEG conjugates

Publications (2)

Publication Number Publication Date
BG104484A true BG104484A (bg) 2000-12-29
BG64815B1 BG64815B1 (bg) 2006-05-31

Family

ID=8227732

Family Applications (1)

Application Number Title Priority Date Filing Date
BG10448A BG64815B1 (bg) 1997-12-03 2000-05-29 Сайт - специфично получаване на конюгати от полиетилен- гликол - grf

Country Status (29)

Country Link
US (3) US6528485B1 (bg)
EP (2) EP0922446A1 (bg)
JP (2) JP2001524505A (bg)
KR (1) KR100561768B1 (bg)
CN (1) CN1149967C (bg)
AR (1) AR017780A1 (bg)
AT (1) ATE236607T1 (bg)
AU (1) AU755285B2 (bg)
BG (1) BG64815B1 (bg)
BR (1) BR9815159A (bg)
CA (1) CA2312004C (bg)
DE (1) DE69813291T2 (bg)
DK (1) DK1037587T3 (bg)
EA (1) EA004269B1 (bg)
EE (1) EE200000319A (bg)
ES (1) ES2194376T3 (bg)
HU (1) HUP0100507A3 (bg)
IL (2) IL136551A0 (bg)
NO (1) NO327238B1 (bg)
NZ (1) NZ504570A (bg)
PL (1) PL192082B1 (bg)
PT (1) PT1037587E (bg)
SI (1) SI1037587T1 (bg)
SK (1) SK8242000A3 (bg)
TR (1) TR200001615T2 (bg)
TW (1) TWI254641B (bg)
UA (1) UA73716C2 (bg)
WO (1) WO1999027897A1 (bg)
ZA (1) ZA9811068B (bg)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
AU9558901A (en) * 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US8048408B2 (en) * 2002-01-16 2011-11-01 Biocompatibles Uk Limited Polymer conjugates
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
CN100357313C (zh) * 2003-01-18 2007-12-26 派格斯菲尔有限公司 非靶位点胺基被保护的肽,其制备方法以及使用该肽制备特异性地结合的peg肽的方法
WO2005010040A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
WO2005010163A2 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
AU2004311630A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
AU2005209318B2 (en) * 2004-01-28 2010-02-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
EP1907067B2 (en) * 2005-07-26 2017-06-28 Solvay USA Inc. Polymers with pendant poly(alkyleneoxy) substituent groups and their use in personal care applications
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2581450B1 (en) 2006-05-02 2018-08-15 MedImmune Limited Non-natural amino acid substituted polypeptides
WO2008019214A1 (en) * 2006-08-04 2008-02-14 Prolong Pharmaceuticals, Inc. Modified erythropoietin
US20080083154A1 (en) * 2006-10-05 2008-04-10 Timothy M Gregory Bait retention fish hook
RU2345608C2 (ru) * 2007-01-09 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Северо-Кавказский государственный технический университет" Вареная колбаса с использованием pse свинины и способ ее производства
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
JP2011520769A (ja) * 2007-09-21 2011-07-21 サイトイミューン サイエンシズ インコーポレイテッド ナノ治療コロイド金属組成物および方法
CA2706700A1 (en) * 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
AU2009313619A1 (en) * 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
SG174320A1 (en) 2009-03-20 2011-10-28 Hanmi Holdings Co Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
WO2010121351A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
EP2445536B1 (en) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Methods and compositions using peptides and proteins with c-terminal elements
WO2011057027A2 (en) 2009-11-04 2011-05-12 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
US8361964B2 (en) 2011-04-21 2013-01-29 Theratechnologies Inc. Growth hormone releasing factor (GRF) analogs and uses thereof
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
US10519239B2 (en) 2015-05-28 2019-12-31 Institut National De La Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
CA3021231A1 (en) * 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
CN110317826B (zh) * 2019-05-22 2020-11-10 中国农业大学 调控PvGRF9含量或活性的物质在调控植物茎生长发育中的应用
WO2021119827A1 (en) 2019-12-19 2021-06-24 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
WO2021133407A1 (en) 2019-12-27 2021-07-01 Compagnie Generale Des Etablissements Michelin Rubber mix with high specific surface area and high structure acetylene carbon black
EP4284828A1 (en) 2021-01-28 2023-12-06 Talem Therapeutics LLC Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
US20260092121A1 (en) 2022-10-14 2026-04-02 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
EP0400472B1 (en) * 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
ZA914983B (en) * 1990-06-29 1992-03-25 Hoffmann La Roche His-grf-analogs
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
EP0525838A3 (en) * 1991-04-09 1993-02-10 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
EP0518295A3 (en) * 1991-06-14 1993-09-01 Millipore Corporation Allyl side chain protection in peptide synthesis
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1997017367A1 (en) * 1995-11-03 1997-05-15 Theratechnologies Inc. Method of grf peptides synthesis

Also Published As

Publication number Publication date
BG64815B1 (bg) 2006-05-31
JP2001524505A (ja) 2001-12-04
CN1280483A (zh) 2001-01-17
NO327238B1 (no) 2009-05-18
NO20002664D0 (no) 2000-05-24
WO1999027897A1 (en) 1999-06-10
SI1037587T1 (en) 2003-08-31
DE69813291D1 (de) 2003-05-15
AR017780A1 (es) 2001-10-24
TWI254641B (en) 2006-05-11
JP5431874B2 (ja) 2014-03-05
ZA9811068B (en) 1999-06-28
PL192082B1 (pl) 2006-08-31
EP0922446A1 (en) 1999-06-16
EE200000319A (et) 2001-08-15
ATE236607T1 (de) 2003-04-15
HUP0100507A3 (en) 2001-11-28
IL136551A (en) 2008-12-29
NO20002664L (no) 2000-07-13
PT1037587E (pt) 2003-08-29
NZ504570A (en) 2003-10-31
UA73716C2 (en) 2005-09-15
BR9815159A (pt) 2000-10-10
DE69813291T2 (de) 2003-11-13
US20050159353A1 (en) 2005-07-21
SK8242000A3 (en) 2001-01-18
US6869932B2 (en) 2005-03-22
CA2312004A1 (en) 1999-06-10
EA004269B1 (ru) 2004-02-26
DK1037587T3 (da) 2003-07-28
KR20010032494A (ko) 2001-04-25
EP1037587A1 (en) 2000-09-27
AU1563399A (en) 1999-06-16
CN1149967C (zh) 2004-05-19
IL136551A0 (en) 2001-06-14
US6528485B1 (en) 2003-03-04
AU755285B2 (en) 2002-12-05
US7317002B2 (en) 2008-01-08
PL341139A1 (en) 2001-03-26
EP1037587B1 (en) 2003-04-09
HUP0100507A2 (hu) 2001-08-28
EA200000601A1 (ru) 2000-12-25
HK1034203A1 (en) 2001-10-19
US20040029794A1 (en) 2004-02-12
WO1999027897A9 (en) 1999-09-30
ES2194376T3 (es) 2003-11-16
TR200001615T2 (tr) 2000-12-21
KR100561768B1 (ko) 2006-03-16
JP2010024245A (ja) 2010-02-04
CA2312004C (en) 2009-05-19

Similar Documents

Publication Publication Date Title
CA2312004A1 (en) Site-specific preparation of polyethylene glycol-grf conjugates
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
EP1568772A3 (en) Human growth hormone variants
GEP20063860B (en) Chemically-modified human growth hormone conjugates
NO975555D0 (no) Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein
KR880001701A (ko) 신규한 펩티드
EP2112161A3 (en) Peptides that lower blood glucose levels
CA2064689A1 (en) Stabilized protein or peptide conjugates
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
TR200003161T2 (tr) Poliol-IFN-Beta konjugatları
BG105461A (bg) Модифицирани пептиди като терапевтични агенти
ATE369878T1 (de) Träger-pharmaka-konjugate
IL87055A (en) Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
KR970701731A (ko) 펩타이드 백신 및 이와 관련된 방법(Peptide vaccines and methods relating thereto)
KR910007858A (ko) 초기-촉진 및 향상된 진통제로서의 s(+)-이부프로펜-l-아미노산 및 s(+)-이부프로펜-d-아미노산
KR900003205A (ko) 제약 화합물
RU2002130203A (ru) Пептидные конъюгаты для доставки лекарственного средства
KR880012641A (ko) 아미노산 유도체
DE3883600D1 (de) Redox-aminsäuren und diese enthaltende Peptide.
NZ234173A (en) Alpha-melanocyte stimulating hormone derivative (alphamsh)-targetted moiety conjugate
WO1993002708A1 (en) Novel reagent for tumour imaging and therapy
WO1997010262A1 (fr) Derives peptidiques
CA2257973A1 (en) T cell antigen receptor peptides
RU96113877A (ru) Конъюгаты биологически активных веществ (бав) с альфа-фетопротеином (афп), обладающие избирательным действием по отношению к раковым опухолям, способ их получения (варианты) и фармацевтическая композиция на их основе